Search

Your search keyword '"Macconaill, Laura E."' showing total 369 results

Search Constraints

Start Over You searched for: Author "Macconaill, Laura E." Remove constraint Author: "Macconaill, Laura E."
369 results on '"Macconaill, Laura E."'

Search Results

1. Author Correction: Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

2. Molecular profiling of 888 pediatric tumors informs future precision trials and data-sharing initiatives in pediatric cancer

4. Twists and Turns from 'Tumor in Tumor' Profiling: Surveillance of CLL leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis

5. Molecular profiling identifies targeted therapy opportunities in pediatric solid cancer

6. MatchMiner: an open-source platform for cancer precision medicine

8. Genotyping cancer-associated genes in chordoma identifies mutations in oncogenes and areas of chromosomal loss involving CDKN2A, PTEN, and SMARCB1.

9. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific raf inhibitor PLX4032

10. Supplementary Figures 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

11. Data from AACR Project GENIE: Powering Precision Medicine through an International Consortium

12. Table S3 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

13. Supplementary Appendix from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

14. Data from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

15. Supplemental Methods, Supplemental Tables 1-2, Supplemental Figures 1-4 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

16. Supplemental File 1 from AACR Project GENIE: Powering Precision Medicine through an International Consortium

17. Supplementary Methods, Tables 1-9, Figure Legends 1-3 from High-Throughput Detection of Actionable Genomic Alterations in Clinical Tumor Samples by Targeted, Massively Parallel Sequencing

20. eFigure1 from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

21. Supplementary Table from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

22. Supplementary Figure from Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

23. Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

24. Supplementary Data from Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions

25. Supplementary Methods and Results from Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer

26. Supplementary Figures from Genomic Characterization of de novo Metastatic Breast Cancer

27. Supplementary File 3 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

28. Supplementary File 2 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

29. Supplementary File 1 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

30. Supplementary File 5 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

31. Supplementary File 4 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

32. Supplementary File 6 from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

33. Materials and Methods, Legends, Tables and Figures from Genome-Wide Functional Synergy between Amplified and Mutated Genes in Human Breast Cancer

35. Ancestry-driven recalibration of tumor mutational burden and disparate clinical outcomes in response to immune checkpoint inhibitors

36. Identification and Management of Pathogenic Variants in BRCA1, BRCA2, and PALB2 in a Tumor-Only Genomic Testing Program

37. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1

38. Integrated Clinico-Genomic Analysis of Genetic Ancestry in 1,614 Patients With Cancer Treated With Immune Checkpoint Inhibitors

39. MEK1 Mutations Confer Resistance to MEK and B-RAF Inhibition

40. High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade

41. Multicenter Feasibility Study of Tumor Molecular Profiling to Inform Therapeutic Decisions in Advanced Pediatric Solid Tumors: The Individualized Cancer Therapy (iCat) Study

44. Role of BRAFV600E in the First Preclinical Model of Multifocal Infiltrating Myopericytoma Development and Microenvironment

45. Genomic aberrations in cervical adenocarcinomas in Hong Kong Chinese women

47. Twists and turns from “tumor in tumor” profiling: surveillance of chronic lymphocytic leukemia (CLL) leads to detection of a lung adenocarcinoma, whose genomic characterization alters the original hematologic diagnosis

48. Identification and management of pathogenic mutations in BRCA1, BRCA2, and PALB2 in a tumor-only genomic testing program.

49. Genetic ancestry and clinical outcomes to immune checkpoint inhibitors among seven common cancers.

Catalog

Books, media, physical & digital resources